A partnership comprising software company Euformatics, ViennaLab Diagnostics and Oncompass Medicine, have been awarded with one of three Phase 2 contracts to research and develop an economically sustainable liquid biopsy diagnostics solution based on DNA and RNA molecular profiling in cancer patients for a buyer consortium including some of the highest ranking European hospitals(1) from Germany, France, Italy, Spain and Belgium for the OncNGS pre-commercial procurement Consortium funded by the EU. Click to read more.